- Home
- RPTX vs CLSD Comparison
RPTX vs CLSD Comparison
Compare RPTX & CLSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPTX
- CLSD
- Stock Information
- Founded
- RPTX 2016
- CLSD 2011
- Country
- RPTX Canada
- CLSD United States
- Employees
- RPTX N/A
- CLSD N/A
- Industry
- RPTX Biotechnology: Pharmaceutical Preparations
- CLSD Biotechnology: Pharmaceutical Preparations
- Sector
- RPTX Health Care
- CLSD Health Care
- Exchange
- RPTX Nasdaq
- CLSD Nasdaq
- Market Cap
- RPTX 69.2M
- CLSD 68.4M
- IPO Year
- RPTX 2020
- CLSD 2016
- Fundamental
- Price
- RPTX $1.69
- CLSD $0.35
- Analyst Decision
- RPTX Strong Buy
- CLSD Hold
- Analyst Count
- RPTX 3
- CLSD 4
- Target Price
- RPTX $4.50
- CLSD $4.33
- AVG Volume (30 Days)
- RPTX 91.2K
- CLSD 569.9K
- Earning Date
- RPTX 11-06-2025
- CLSD 08-08-2025
- Dividend Yield
- RPTX N/A
- CLSD N/A
- EPS Growth
- RPTX N/A
- CLSD N/A
- EPS
- RPTX N/A
- CLSD N/A
- Revenue
- RPTX $250,000.00
- CLSD $4,166,000.00
- Revenue This Year
- RPTX N/A
- CLSD $98.20
- Revenue Next Year
- RPTX N/A
- CLSD $213.77
- P/E Ratio
- RPTX N/A
- CLSD N/A
- Revenue Growth
- RPTX N/A
- CLSD N/A
- 52 Week Low
- RPTX $0.89
- CLSD $0.29
- 52 Week High
- RPTX $4.07
- CLSD $1.65
- Technical
- Relative Strength Index (RSI)
- RPTX 66.56
- CLSD 33.22
- Support Level
- RPTX $1.66
- CLSD $0.39
- Resistance Level
- RPTX $1.60
- CLSD $0.43
- Average True Range (ATR)
- RPTX 0.06
- CLSD 0.03
- MACD
- RPTX 0.01
- CLSD 0.00
- Stochastic Oscillator
- RPTX 80.95
- CLSD 14.68
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.